论文部分内容阅读
目的:评价母牛分枝杆菌(微卡)辅助治疗支气管哮喘的有效性与安全性。方法:选取门诊哮喘患者30例,均在初诊时及治疗4周后详细记录其哮喘发作次数、临床症状体征积分、FEV1、FEV1%、PEF,雾化吸入沙丁胺醇控制哮喘急性发作,评价母牛分支杆菌疗效。结果:治疗前后相比,患者哮喘发作次数有显著性差异(P<0.01),临床评分有显著性差异(P<0.01)。治疗前后肺通气功能比较,FVC治疗前后无显著性差异(P>0.05)、FEV1治疗前后无显著性差异(P>0.05)、FEV1%治疗前后无显著性差异(P>0.05),而PEF有显著性差异(P<0.01)。受试者中1例发热,余无不良事件发生。结论:母牛分枝杆菌菌苗联合沙丁胺醇对哮喘患者有较好的疗效,且安全性良好。
Objective: To evaluate the efficacy and safety of mycobacterium vaccae (micro-card) in adjuvant treatment of bronchial asthma. Methods: Thirty outpatients with asthma were selected. The number of asthma attacks, the scores of clinical symptoms and signs, FEV1, FEV1%, PEF, and salbutamol inhalation were used to control the asthma exacerbation, Bacillus efficacy. Results: Before and after treatment, the number of patients with asthma attack was significantly different (P <0.01), clinical scores were significantly different (P <0.01). There was no significant difference between before and after treatment of FVC (P> 0.05), before and after treatment of FEV1 (P> 0.05), there was no significant difference before and after FEV1% treatment (P> 0.05) Significant difference (P <0.01). One of the subjects had fever, and no adverse event occurred. Conclusion: Mycobacterium vaccae combined with salbutamol has a good effect on patients with asthma and has good safety.